Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FDA adds severe liver risk warning to Elevidys, restricts use to ambulatory boys age 4+ with Duchenne muscular dystrophy.
The FDA has updated Elevidys' label with a boxed warning for acute liver failure and serious liver injury, restricting its use to ambulatory boys aged 4 and older with Duchenne muscular dystrophy.
The change follows three deaths, including two in non-ambulatory patients, prompting removal of that group from the approved indication.
The therapy is now contraindicated in patients with certain DMD gene deletions, and strict monitoring and immunosuppressive regimens are required.
Sarepta has paused shipments to non-ambulatory patients and will study a new immunosuppression approach to potentially restore access.
5 Articles
La FDA añade advertencia de riesgo hepático grave a Elevidys, restringe el uso a niños ambulatorios de 4 años o más con distrofia muscular de Duchenne.